Liberia has commenced the first large-scale trials of an experimental Ebola vaccine.
Scientists aim to immunize around 30,000 volunteers and health care workers in the country starting Monday, the BBC reports. The trial will involve injecting each of them with a tiny amount of chimpanzee cold virus that carries safe genetic material of Ebola, tricking the human body into producing an immune response.
The medicine has been hidden in a secret location in the country since it arrived one week ago.
British pharmaceutical and healthcare company GlaxoSmithKline developed the vaccine alongside the U.S. National Institutes of Health; should the trial be successful, it would be the first preventative vaccine against the killer virus.
More than 8,500 people have died during the current Ebola outbreak, with 3,600 succumbing to the disease in Liberia alone. The number of new Ebola cases is in steady decline, however.
[BBC]
More Must-Reads from TIME
- Cybersecurity Experts Are Sounding the Alarm on DOGE
- Meet the 2025 Women of the Year
- The Harsh Truth About Disability Inclusion
- Why Do More Young Adults Have Cancer?
- Colman Domingo Leads With Radical Love
- How to Get Better at Doing Things Alone
- Michelle Zauner Stares Down the Darkness
Write to Helen Regan at helen.regan@timeasia.com